Skip to main content

Table 2 Country context

From: Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries

Country Population size, 2019 [75] GDP—per capita (PPP) [79] (2017 est.) in US$ Population at risk of malaria (%), 2019 [75] Elimination target Proportion of P. falciparum, P. vivax [18] Funding dominance external vs domestic [18] Treatment Guidelines Last update of guidelines Comment
Cambodia 16,486,542 $4000 11,659,118 (71%) P. falciparum by 2023 and all species of malaria by 2025 [80, 81] P. falciparum: 58%
P. vivax: 41%
External PQ14 (low dose) without G6PD testing 2014 guidelines were reviewed, but not changed, in 2017 While the current guidelines do not require G6PD testing (despite the WHO report stating), qualitative G6PD testing is being used in a pilot involving 88 public health facilities in 4 provinces between November 2019 and September 2020. This pilot is expected to inform the 2020 review of the guidelines
Ethiopia 112,078,736 $2200 76,213,540 (77%) 2030 [82] P. falciparum: 69%
P. vivax: 30%
External PQ14 (low dose) without G6PD testing 2018  
Indonesia 270,625,584 $12,400 270,625,584 (100%) 2030 [81] P. falciparum: 63%
P. vivax: 37%
Approx. 40% domestic PQ14 (low dose) without G6PD testing   
Pakistan 216,565,320 $540 212,907,532 (98%) 2030 [81] P. falciparum: 21%
P. vivax: 78%
Nearly 50% domestic PQ14 (low dose) G6PD testing recommended where possible, but not required (although 2018 WHO report states it as a requirement) 2018 Guidelines will next be updated after the 2020 therapeutic efficacy study results are available
Papua New Guinea 8,776,119 $370 8,776,119 (100%) 2030 [81] P. falciparum: 76%
P. vivax: 23%
External PQ14 (low dose) without G6PD testing 2011 Research is planned in 2020–2021 to inform the next version of the guidelines which—pending research findings and WHO recommendations—may include PQ7 and G6PD testing for confirmed vivax cases
Sri Lanka 22,889,201 $1290 0 (0%) Elimination reached in 2016 [83] NA   PQ14 (low dose) with qualitative G6PD testing 2016 Next planned review of the guidelines will take place in 2021, depending on the 2020 mid-term review findings and timeline
Vietnam 96,462,116 $6900 71,091,518 (74%) P. falciparum by 2020 and all species of malaria by 2030 [81] P. falciparum: 64%
P. vivax: 35%
Approx. 75% external PQ14 (low dose) without G6PD testing 2016 The 2018 review resulted in a decision that no updates were required. New guidelines are currently pending review with approval from the MoH expected in 2020 and will recommend but not require G6PD testing where possible, before treatment with PQ14